MedTrace Logo

Allogeneic BM-MSC's in Patients With Lumbar Facet Arthropathy

NCT06001853 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-01-13

No results posted yet for this study

Summary

The purpose of this research study is to evaluate the safety and effect of bone marrow-derived stem cells for the treatment of low back pain.

Conditions

  • Facet-Mediated Low Back Pain

Interventions

DRUG

BM-MSC injection

BM-MSCs at the dose 10 x 106 in 1 ml per facet joint for a total of 2 joints

DRUG

DSMO Injection

After 6 months, patients randomized to Arm B: DMSO will be unblinded and re-assigned to Arm A: treatment then be followed for 12 months.

Sponsors & Collaborators

Principal Investigators

  • Wenchun Qu, MD, PhD · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-03
Primary Completion
2026-07-31
Completion
2026-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06001853 on ClinicalTrials.gov